Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO News In Brief: IDEC Pharmaceuticals IDEC-C2B8

Executive Summary

IDEC Pharmaceuticals IDEC-C2B8: Overall response rate of 47.9% reported in preliminary results of Phase III pivotal trial of single-agent antibody treatment for patients with relapsed low-grade or follicular non-Hodgkin's lymphoma. Fifty of 166 evaluable patients have been analyzed and full results should be available in December 1996, the company said. The tumor marker gene, bcl-2, reverted from positive to negative in the peripheral blood of 12 of 16 patients and in the bone marrow of six of 12 patients evaluated. IDEC is developing IDEC-C2B8 in collaboration with Genentech, Roche and Zenyaku Kogyo of Japan...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel